Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
39 studies found for:    " February 24, 2010":" March 26, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Completed PENTA Fosamprenavir Study
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: Exposure to licensed dose of FPV (+/- 20% of 18mg/kg BID + RTV)
22 Completed
Has Results
Evaluation of Kaletra Therapy Over the Long-term
Condition: Human Immunodeficiency Virus
Intervention: Drug: Lopinavir/Ritonavir (Kaletra)
23 Completed Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet
Condition: Human Immunodeficiency Virus
Intervention:
24 Completed Kaletra in Combination With Antiretroviral Agents
Condition: Human Immunodeficiency Virus
Intervention:
25 Completed
Has Results
Observational Data Analysis in EuroSIDA (MK-0518-058)
Condition: HIV-1 Infections
Intervention:
26 Completed Cardiovascular Radiologic and Metabolic Assessment in HIV: An Investigation of Pathophysiology
Conditions: HIV;   Cardiovascular Disease
Intervention:
27 Recruiting Antiretroviral Pregnancy Registry (APR)-Risk of Birth Defects
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: Any Antiretroviral Therapy
28 Completed
Has Results
Long-term Effectiveness and Safety in Hepatitis-co-infected Patients
Condition: Human Immunodeficiency Virus-Infection
Intervention: Drug: Lopinavir/Ritonavir (Kaletra)
29 Completed GSK1349572 Drug Interaction Study With Efavirenz
Conditions: Infections, Human Immunodeficiency Virus and Herpesviridae;   Healthy
Interventions: Drug: GSK1349572;   Drug: Efavirenz
30 Completed
Has Results
Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
Condition: Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome
Intervention: Biological: Serostim
31 Completed Investigation of the Safety of an HIV-1 Vaccine Given Intra-muscularly and Intra-nasally to Healthy Female Subjects
Condition: HIV-1
Intervention: Biological: MYM-V101
32 Completed A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days
Condition: HIV-1 Infection
Intervention: Drug: Bevirimat
33 Completed A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients
Condition: HIV-1 Infection
Interventions: Drug: TBR-652;   Drug: TBR-652 Matching Placebo;   Drug: TBR-652 50 mg;   Drug: TBR-652 75 mg;   Drug: TBR-652 100 mg;   Drug: TBR-652 150 mg
34 Completed Fractures Stratified by HIV and Antiretroviral Therapy (ART) Status
Conditions: Fracture;   Infection, Human Immunodeficiency Virus
Interventions: Other: No Antiretroviral (ARV) Drug Exposure;   Drug: Any Antiretroviral (ARV) Drug Exposure
35 Completed Safety of Cotrimoxazole in HIV- and HAART-exposed Infants
Conditions: Acquired Immunodeficiency Syndrome;   Infant, Newborn;   Anemia;   Neutropenia;   HIV Infections
Intervention: Drug: cotrimoxazole
36 Completed A Computer-Based Parent/Adolescent HIV Communication Intervention for Latinos
Conditions: HIV/AIDS;   STD;   Pregnancy
Intervention: Behavioral: Computer-based parent-adolescent HIV communication
37 Completed
Has Results
Mesalamine to Reduce T Cell Activation in HIV Infection
Conditions: HIV Infections;   Sexually Transmitted Diseases;   Immune System Diseases;   Lentivirus Infections;   Acquired Immunodeficiency Syndrome
Interventions: Drug: Mesalamine (5-aminosalicylic acid, Apriso);   Drug: Placebo
38 Completed Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine
Condition: AIDS
Interventions: Procedure: Blood collection;   Biological: GSK HIV vaccine 732462
39 Suspended Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
Conditions: Burkitt Lymphoma;   Diffuse Large B-cell Lymphoma, c-MYC Positive;   Plasmablastic Lymphoma
Interventions: Drug: EPOCH-R;   Drug: EPOCH-RR

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-39) Next Page   
Study has passed its completion date and status has not been verified in more than two years.